Jasper Therapeutics completes all-stock acquisition of Kira Pharmaceuticals and $132M PIPE

Jasper Therapeutics, Inc.

Jasper acquires Kira in all-stock deal; pre-deal Jasper holders own ~6.68%, Kira holders ~49.86%, PIPE investors ~43.46% of combined company.
Concurrent $132M private placement co-led by Affinity Asset Advisors and Ikarian Capital; expected to close July 20, 2026.
Kira out-licenses KP-301 and KP-402 to Mirador Therapeutics for $12M upfront plus potential milestones.
Combined company cash runway through H2 2028; key milestones include KP-104 Phase 2 renal data in Q4 2026 and end-of-Phase 2 FDA meeting for PNH in H1 2027.
Briquilimab pre-BLA meeting for SCID expected in Q1 2027; KP-701 IND/CTA filing in Q1 2027 with first-in-human data in Q3 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.